This session covers a wide range of topics relevant to the current landscape of viral hepatitis, including elimination efforts, resistance to direct-acting antivirals (DAAs), surveillance methods during and after therapy. This talk provides you with valuable insights through an up-to-date overview of the latest developments and challenges in the field.


  • Thomas Berg (Moderator)
  • Jordan Feld (Faculty)
  • Norah Terrault (Faculty)
  • Heiner Wedemeyer (Faculty)

This episode is scheduled in honour of the United States’ Viral Hepatitis Awareness Month.

This EASL Studio is supported by GSK and Vir Biotechnology. EASL has received no input from GSK or Vir Biotechnology with regards to the content of this programme.

Related episodes

ℹ️ Please click here to access the podcast version of this EASL Studio episode.

Log in to post comments